Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures
Author
Abstract
Suggested Citation
Note: EH
Download full text from publisher
References listed on IDEAS
- Ulrike Malmendier & Geoffrey Tate, 2005.
"CEO Overconfidence and Corporate Investment,"
Journal of Finance, American Finance Association, vol. 60(6), pages 2661-2700, December.
- Ulrike Malmendier & Geoffrey Tate, 2004. "CEO Overconfidence and Corporate Investment," NBER Working Papers 10807, National Bureau of Economic Research, Inc.
- Henry Grabowski, 2003. "Patents and New Product Development in the Pharmaceutical and Biotechnology Industries," Levine's Working Paper Archive 618897000000000661, David K. Levine.
- Henry G. Grabowski, 1968. "The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries," Journal of Political Economy, University of Chicago Press, vol. 76(2), pages 292-292.
- Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
- Bronwyn H. Hall., 1992.
"Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?,"
Economics Working Papers
92-194, University of California at Berkeley.
- Bronwyn H. Hall, 1992. "Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?," NBER Working Papers 4096, National Bureau of Economic Research, Inc.
- John A. Vernon, 2005. "Examining the link between price regulation and pharmaceutical R&D investment," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 1-16, January.
- R. Glenn Hubbard, 1998.
"Capital-Market Imperfections and Investment,"
Journal of Economic Literature, American Economic Association, vol. 36(1), pages 193-225, March.
- R. Glenn Hubbard, 1997. "Capital-Market Imperfections and Investment," NBER Working Papers 5996, National Bureau of Economic Research, Inc.
- Grabowski, Henry G & Vernon, John M, 1992. "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act," Journal of Law and Economics, University of Chicago Press, vol. 35(2), pages 331-350, October.
- Hall, Bronwyn H., 1992. "Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?," Department of Economics, Working Paper Series qt5j59j6x3, Department of Economics, Institute for Business and Economic Research, UC Berkeley.
- Vernon, John A. & Golec, Joseph H. & Lutter, Randall & Nardinelli, Clark, 2009. "An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending," The Quarterly Review of Economics and Finance, Elsevier, vol. 49(4), pages 1260-1274, November.
- David Reiffen & Michael R. Ward, 2005. "Generic Drug Industry Dynamics," The Review of Economics and Statistics, MIT Press, vol. 87(1), pages 37-49, February.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022.
"Generic competition and the incentives for early-stage pharmaceutical innovation,"
Research Policy, Elsevier, vol. 51(10).
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
- Ali Bonakdar Tehrani & Norman V. Carroll, 2017. "The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 513-520, August.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Bryan P. Schmutz & Rexford E. Santerre, 2013. "Examining The Link Between Cash Flow, Market Value, And Research And Development Investment Spending In The Medical Device Industry," Health Economics, John Wiley & Sons, Ltd., vol. 22(2), pages 157-167, February.
- Vernon, John A. & Golec, Joseph H. & Lutter, Randall & Nardinelli, Clark, 2009. "An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending," The Quarterly Review of Economics and Finance, Elsevier, vol. 49(4), pages 1260-1274, November.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- John A. Vernon, 2005. "Examining the link between price regulation and pharmaceutical R&D investment," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 1-16, January.
- John Vernon & Joseph Golec & J. Stevens, 2010. "Comparative Effectiveness Regulations and Pharmaceutical Innovation," PharmacoEconomics, Springer, vol. 28(10), pages 877-887, October.
- Guariglia, Alessandra & Liu, Pei, 2014. "To what extent do financing constraints affect Chinese firms' innovation activities?," International Review of Financial Analysis, Elsevier, vol. 36(C), pages 223-240.
- Alfredo Bobillo & Juan Rodriguez Sanz & Fernando Tejerina Gaite, 2009. "Investment Decisions, Liquidity, and Institutional Activism: An International Study," Journal of Business Ethics, Springer, vol. 87(1), pages 25-40, April.
- Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
- Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
- Dirk Czarnitzki & Hanna Hottenrott & Susanne Thorwarth, 2011.
"Industrial research versus development investment: the implications of financial constraints,"
Cambridge Journal of Economics, Cambridge Political Economy Society, vol. 35(3), pages 527-544.
- Czarnitzki, Dirk & Hottenrott, Hanna & Thorwarth, Susanne, 2009. "Industrial research versus development investment: the implications of financial constraints," ZEW Discussion Papers 09-049, ZEW - Leibniz Centre for European Economic Research.
- Valérie Revest & Alessandro Sapio, 2012.
"Financing technology-based small firms in Europe: what do we know?,"
Small Business Economics, Springer, vol. 39(1), pages 179-205, July.
- Valérie Revest & Alessandro Sapio, 2012. "Financing technology-based small firms in Europe: what do we know?," Post-Print halshs-00606802, HAL.
- Hanna Hottenrott & Bronwyn H. Hall & Dirk Czarnitzki, 2016.
"Patents as quality signals? The implications for financing constraints on R&D,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 25(3), pages 197-217, April.
- Czarnitzki, Dirk & Hall, Bronwyn H. & Hottenrott, Hanna, 2014. "Patents as quality signals? The implications for financing constraints on R&D," DICE Discussion Papers 133, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
- Hottenrott, Hanna & Hall, Bronwyn H & Czarnitzki, Dirk, 2016. "Patents as quality signals? The implications for financing constraints on R&D," Department of Economics, Working Paper Series qt4cr497qv, Department of Economics, Institute for Business and Economic Research, UC Berkeley.
- Hottenrott H. & Czarnitzki D. & Hall, B.H., 2014. "Patents as quality signals? The implications for financing constraints on R&D," MERIT Working Papers 2014-013, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- Bronwyn Hall, 2014. "Patents as Quality Signals? The Implications for Financing Constraints on R&D," National Institute of Economic and Social Research (NIESR) Discussion Papers 430, National Institute of Economic and Social Research.
- Dirk Czarnitzki & Bronwyn H. Hall & Hanna Hottenrott, 2014. "Patents as Quality Signals? The Implications for Financing Constraints on R&D," NBER Working Papers 19947, National Bureau of Economic Research, Inc.
- Czarnitzki, Dirk & Hall, Bronwyn H. & Hottenrott, Hanna, 2014. "Patents as quality signals? The implications for financing constraints on R&D," ZEW Discussion Papers 14-023, ZEW - Leibniz Centre for European Economic Research.
- Giorgio Fagiolo & Alessandra Luzzi, 2006.
"Do liquidity constraints matter in explaining firm size and growth? Some evidence from the Italian manufacturing industry,"
Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 15(1), pages 1-39, February.
- Giorgio Fagiolo & Alessandra Luzzi, 2004. "Do Liquidity Constraints Matter in Explaining Firm Size and Growth? Some Evidence from the Italian Manufacturing Industry," LEM Papers Series 2004/08, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
- Hanna Hottenrott & Bettina Peters, 2012.
"Innovative Capability and Financing Constraints for Innovation: More Money, More Innovation?,"
The Review of Economics and Statistics, MIT Press, vol. 94(4), pages 1126-1142, November.
- Hottenrott, Hanna & Peters, Bettina, 2009. "Innovative capability and financing constraints for innovation: More money, more innovation?," ZEW Discussion Papers 09-081, ZEW - Leibniz Centre for European Economic Research.
- Hottenrott, Hanna & Peters, Bettina, 2012. "Innovative capability and financing constraints for innovation: More money, more innovation?," ZEW Discussion Papers 09-081 [rev.2], ZEW - Leibniz Centre for European Economic Research.
- Hottenrott, Hanna & Peters, Bettina, 2011. "Innovative capability and financing constraints for innovation: More money, more innovation?," ZEW Discussion Papers 09-081 [rev.], ZEW - Leibniz Centre for European Economic Research.
- Masayuki MORIKAWA, 2012. "Financial Constraints in Intangible Investments: Evidence from Japanese firms," Discussion papers 12045, Research Institute of Economy, Trade and Industry (RIETI).
- Lee, Daeyong, 2018. "Impact of the excise tax on firm R&D and performance in the medical device industry: Evidence from the Affordable Care Act," Research Policy, Elsevier, vol. 47(5), pages 854-871.
- Mario Tirelli & Luca Spinesi, 2021.
"R&D financing and growth,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 30(1), pages 24-47, January.
- Luca, Spinesi & Mario, Tirelli, 2018. "R&D financing and growth," MPRA Paper 86860, University Library of Munich, Germany.
- Luca Spinesi & Mario Tirelli, 2019. "R&D Financing And Growth," Departmental Working Papers of Economics - University 'Roma Tre' 0249, Department of Economics - University Roma Tre.
- Garcia-Vega, Maria, 2006. "Does technological diversification promote innovation?: An empirical analysis for European firms," Research Policy, Elsevier, vol. 35(2), pages 230-246, March.
- Jason G. Cummins & Kevin A. Hassett & Stephen D. Oliner, 2006.
"Investment Behavior, Observable Expectations, and Internal Funds,"
American Economic Review, American Economic Association, vol. 96(3), pages 796-810, June.
- Cummins, Jason & Hassett, Kevin & Oliner, Stephen, 1997. "Investment Behavior, Observable Expectations and Internal Funds," Working Papers 97-30, C.V. Starr Center for Applied Economics, New York University.
- Jason G. Cummins & Kevin A. Hassett & Stephen D. Oliner, 1999. "Investment behavior, observable expectations, and internal funds," Finance and Economics Discussion Series 1999-27, Board of Governors of the Federal Reserve System (U.S.).
- Alam, Ashraful & Uddin, Moshfique & Yazdifar, Hassan, 2019. "Institutional determinants of R&D investment: Evidence from emerging markets," Technological Forecasting and Social Change, Elsevier, vol. 138(C), pages 34-44.
More about this item
JEL classification:
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- K0 - Law and Economics - - General
- L0 - Industrial Organization - - General
NEP fields
This paper has been announced in the following NEP Reports:- NEP-HEA-2010-02-20 (Health Economics)
- NEP-INO-2010-02-20 (Innovation)
- NEP-IPR-2010-02-20 (Intellectual Property Rights)
- NEP-PPM-2010-02-20 (Project, Program and Portfolio Management)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:15723. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.